Page 4 - Johnc Jacobs News Today

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the Medicines...

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has...

Residents soon will have access to a third COVID-19 vaccine option this fall.

Novavax’s updated COVID-19 vaccine is approved by the federal government for anyone 12 and older. The non-mRNA vaccine is expected to compete with Pfizer and Moderna shots.

Novavax’s updated COVID-19 vaccine is approved by the federal government for anyone 12 and older. The non-mRNA vaccine is expected to compete with Pfizer and Moderna shots.

Theres now a third choice in the United States for an updated COVID-19 vaccine, from Novavax.

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists covering the healthcare industry stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.

/PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and...

GAITHERSBURG, Md., Oct. 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™

Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) is authorized for active immunization in individuals 12 years of age and older.